Volume | 1,213,741 |
|
|||||
News | - | ||||||
Day High | 36.36 | Low High |
|||||
Day Low | 34.65 |
Share Name | Share Symbol | Market | Stock Type |
---|---|---|---|
Revolution Medicines Inc | RVMD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Previous Close |
---|---|---|---|---|
35.38 | 34.65 | 36.36 | 35.96 | 35.33 |
Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
---|---|---|---|---|---|
12,526 | 1,213,741 | US$ 35.71 | US$ 43,348,294 | - | 15.4401 - 38.73 |
Last Trade | Type | Quantity | Price | Currency |
---|---|---|---|---|
16:49:30 | formt | 397 | US$ 36.05 | USD |
Revolution Medicines (RVMD) Options Flow Summary
Revolution Medicines Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
57.64M | 164.69M | - | 11.58M | -436.37M | -2.65 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Revolution Medicines News
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical RVMD Price Data
Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 36.01 | 37.87 | 34.23 | 35.68 | 1,200,494 | 0.04 | 0.11% |
1 Month | 32.08 | 38.73 | 29.55 | 34.94 | 1,403,314 | 3.97 | 12.38% |
3 Months | 27.87 | 38.73 | 27.46 | 32.13 | 1,513,076 | 8.18 | 29.35% |
6 Months | 20.26 | 38.73 | 18.00 | 27.78 | 1,553,147 | 15.79 | 77.94% |
1 Year | 22.98 | 38.73 | 15.4401 | 27.43 | 1,556,912 | 13.07 | 56.88% |
3 Years | 41.93 | 43.49 | 14.08 | 25.79 | 1,057,190 | -5.88 | -14.02% |
5 Years | 29.35 | 56.18 | 14.08 | 27.29 | 875,126 | 6.70 | 22.83% |
Revolution Medicines Description
Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. |